BR9714364A - Amidas inibidoras da secreção de apo b/mtp - Google Patents
Amidas inibidoras da secreção de apo b/mtpInfo
- Publication number
- BR9714364A BR9714364A BR9714364A BR9714364A BR9714364A BR 9714364 A BR9714364 A BR 9714364A BR 9714364 A BR9714364 A BR 9714364A BR 9714364 A BR9714364 A BR 9714364A BR 9714364 A BR9714364 A BR 9714364A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- apo
- compounds
- mtp
- secretion inhibiting
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000028327 secretion Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000001906 cholesterol absorption Effects 0.000 abstract 1
- 229940125753 fibrate Drugs 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
farmaceuticamente aceitáveis e hidratos. Os compostos são inibidores de Apo B/MTP e são úteis no tra aterosclerose, pancreatite, obesidade, hipercolesdiabetes. Os compostos desta invenção são também úteis em combinação com outros agentes farmacêuticos incluindo inibidores da biossíntese de colesteromente inibidores de HMG-CoA-redutase e inibidores rantes de ácido da bílis; fibratos; inibidores da absorção de colesterol; inibidores de ACAT, inibidíons, antioxidantes e niacina. Esta invenção tambépreparação de compostos de fórmula (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3230796P | 1996-11-27 | 1996-11-27 | |
| PCT/IB1997/001368 WO1998023593A1 (en) | 1996-11-27 | 1997-11-03 | Apo b-secretion/mtp inhibitory amides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9714364A true BR9714364A (pt) | 2000-03-21 |
Family
ID=21864233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9714364A BR9714364A (pt) | 1996-11-27 | 1997-11-03 | Amidas inibidoras da secreção de apo b/mtp |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6121283A (pt) |
| EP (1) | EP0944602A1 (pt) |
| JP (1) | JP3270764B2 (pt) |
| KR (1) | KR100334567B1 (pt) |
| CN (2) | CN1238764A (pt) |
| AP (1) | AP804A (pt) |
| AR (1) | AR010309A1 (pt) |
| AU (1) | AU716151B2 (pt) |
| BG (2) | BG108830A (pt) |
| BR (1) | BR9714364A (pt) |
| CA (1) | CA2272719C (pt) |
| CZ (1) | CZ292160B6 (pt) |
| DZ (1) | DZ2358A1 (pt) |
| EA (1) | EA001539B1 (pt) |
| GT (1) | GT199700122A (pt) |
| HN (1) | HN1997000144A (pt) |
| HR (1) | HRP970642A2 (pt) |
| ID (1) | ID18995A (pt) |
| IL (1) | IL129744A0 (pt) |
| IS (1) | IS5040A (pt) |
| MA (1) | MA26451A1 (pt) |
| NO (1) | NO312760B1 (pt) |
| NZ (1) | NZ335162A (pt) |
| OA (1) | OA11050A (pt) |
| PA (1) | PA8441601A1 (pt) |
| PE (1) | PE17199A1 (pt) |
| SK (1) | SK65499A3 (pt) |
| TN (1) | TNSN97193A1 (pt) |
| TR (1) | TR199901180T2 (pt) |
| TW (1) | TW502023B (pt) |
| UY (1) | UY24789A1 (pt) |
| WO (1) | WO1998023593A1 (pt) |
| YU (1) | YU23499A (pt) |
| ZA (1) | ZA9710641B (pt) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US5919795A (en) * | 1995-06-07 | 1999-07-06 | Pfizer Inc. | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| US5968950A (en) * | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| ES2255311T3 (es) | 1998-10-08 | 2006-06-16 | Smithkline Beecham Plc | Derivados de tetrahidrobenzazepina utiles como moduladores de los receptores d3 de dopamina (agentes anti-psicoticos). |
| GB9826412D0 (en) | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| EA200100704A1 (ru) * | 1998-12-23 | 2002-02-28 | Джи.Ди.Сирл Ллс | Комбинация для применения по сердечно-сосудистым показаниям |
| EP1342475A1 (en) * | 1998-12-23 | 2003-09-10 | G.D. Searle LLC. | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| ATE242007T1 (de) | 1998-12-23 | 2003-06-15 | Searle Llc | Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen |
| DE19929012A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln |
| DE19929031A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln |
| DE19929065A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| AU6824700A (en) * | 1999-07-20 | 2001-02-05 | Novartis Ag | Organic compounds |
| CA2324801A1 (en) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
| IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| CO5271688A1 (es) * | 1999-11-10 | 2003-04-30 | Pfizer Prod Inc | Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales |
| CA2324800A1 (en) * | 1999-11-10 | 2001-05-10 | Mary Anne Hickman | Use of apo b secretion/mtp inhibitors |
| PT1259484E (pt) | 2000-01-18 | 2005-09-30 | Novartis Ag | Carboxamidas uteis como inibidores de proteina de transferencia de triglicerido microsomal e de secrecao de apolipoproteina b |
| KR20070087103A (ko) * | 2000-03-14 | 2007-08-27 | 액테리온 파마슈티칼 리미티드 | 1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
| WO2001077077A1 (en) * | 2000-04-10 | 2001-10-18 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| AU2001277728A1 (en) * | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
| AU2001277727A1 (en) * | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof |
| MXPA03001857A (es) * | 2000-09-01 | 2003-06-04 | Sankyo Co | Composicones medicinales. |
| JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| CN1478077A (zh) * | 2000-10-05 | 2004-02-25 | ����ҩƷ��ҵ��ʽ���� | 作为apo b分泌抑制剂的苯甲酰胺化合物 |
| JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
| US20040157866A1 (en) * | 2001-04-30 | 2004-08-12 | Hisashi Takasugi | Amide compounds |
| CA2450957A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| UA75660C2 (en) * | 2001-06-28 | 2006-05-15 | Pfizer Prod Inc | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| WO2003007888A2 (en) * | 2001-07-20 | 2003-01-30 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| WO2003013516A1 (en) * | 2001-08-10 | 2003-02-20 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| JP2005510564A (ja) * | 2001-11-28 | 2005-04-21 | 藤沢薬品工業株式会社 | アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物 |
| EP1465885A4 (en) | 2002-01-17 | 2005-04-27 | Pharmacia Corp | NOVEL ALKYL / ARYL HYDROXY OR CETOTHIEPINE COMPOUNDS AS INHIBITORS OF BILIARY ACID TRANSPORT OF THE ILEAL TYPE AND ABSORPTION OF TAUROCHOLATE |
| WO2003063822A2 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| WO2003072532A1 (en) | 2002-02-28 | 2003-09-04 | Japan Tobacco Inc. | Ester compound and medicinal use thereof |
| EP1483233A4 (en) * | 2002-03-13 | 2005-12-21 | Univ Tennessee Res Corp | SUBSTITUTED TETRAHYDROISOQUINOLEINE COMPOUNDS, METHODS OF PREPARATION AND USE THEREOF |
| WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| MXPA05006744A (es) * | 2002-12-20 | 2005-09-08 | Pfizer Prod Inc | Inhibidores de la proteina microsomal de transferencia de trigliceridos. |
| BR0317426A (pt) * | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Inibidores de proteìna de transferência de triglicéridos microssomais |
| AU2004222436A1 (en) | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate |
| EP1669345A4 (en) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
| WO2005118548A1 (en) | 2004-03-01 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| NZ549721A (en) | 2004-03-05 | 2010-08-27 | Univ Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| MX2007004973A (es) * | 2004-10-25 | 2007-06-14 | Japan Tobacco Inc | Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion. |
| EP1843819A2 (en) * | 2004-11-15 | 2007-10-17 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
| MX2007005137A (es) | 2004-11-23 | 2007-06-22 | Warner Lambert Co | Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia. |
| JP2006249022A (ja) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法 |
| KR20080015792A (ko) | 2005-04-19 | 2008-02-20 | 서피스 로직스, 인크. | 미소체 트리글리세리드 전달 단백질 및 ａｐｏ－ｂ 분비의저해 |
| EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| EP1998620B1 (en) | 2006-03-10 | 2011-01-12 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| EA201100811A1 (ru) * | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
| CA2648132C (en) | 2006-04-03 | 2019-05-28 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| US20090042835A1 (en) * | 2006-06-02 | 2009-02-12 | Davis Roger A | Compositions and methods for ameliorating hyperlipidemia |
| US20080241869A1 (en) * | 2006-06-02 | 2008-10-02 | San Diego State University Research Foundation | Compositions and methods for ameliorating hyperlipidemia |
| ES2603379T3 (es) * | 2006-10-09 | 2017-02-27 | Roche Innovation Center Copenhagen A/S | Compuestos antagonistas de ARN para la modulación de PCSK9 |
| US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
| EP2076487B1 (en) | 2006-10-24 | 2010-05-26 | Janssen Pharmaceutica N.V. | Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives |
| JO2653B1 (en) | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| WO2008075949A1 (en) * | 2006-12-20 | 2008-06-26 | Friesland Brands B.V. | Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms |
| JP2010513534A (ja) * | 2006-12-21 | 2010-04-30 | エージェリオン ファーマシューティカルズ， インコーポレイテッド | Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法 |
| CA2681406A1 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
| US8580756B2 (en) * | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| EP2162451A4 (en) * | 2007-06-25 | 2012-04-18 | Neurogen Corp | PIPERAZINYL-OXOALKYL-TETRAHYDRO-BETA-CARBOLINE AND RELATED ANALOGUE |
| US20110054011A1 (en) * | 2007-08-30 | 2011-03-03 | Mccullagh Keith | RNA Antagonist Compounds for the Modulation of FABP4/AP2 |
| KR101889518B1 (ko) * | 2007-10-04 | 2018-08-17 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 마이크로ＭＩＲｓ |
| HUE028064T2 (en) | 2007-12-03 | 2016-11-28 | Obe Therapy Biotechnology | Inhibitors of enteropeptidase boropeptide and their use in the treatment of diseases associated with obesity, overweight and / or abnormal fat metabolism |
| EP2280766A1 (en) | 2007-12-11 | 2011-02-09 | CytoPathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
| AU2009221064B2 (en) * | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
| US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
| EP2421970B1 (en) * | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
| WO2011009697A1 (en) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
| AU2014300981B2 (en) | 2013-06-27 | 2017-08-10 | Ricc A/S | Antisense oligomers and conjugates targeting PCSK9 |
| US9856478B2 (en) | 2013-10-30 | 2018-01-02 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| CA2965336A1 (en) | 2014-10-22 | 2016-04-28 | The Board Of Regents Of The University Of Texas System | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof |
| MA54261B1 (fr) | 2019-01-18 | 2025-03-28 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
| US20230285376A1 (en) | 2020-07-29 | 2023-09-14 | Amryt Pharmaceuticals Inc. | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
| US20240190847A1 (en) * | 2021-03-26 | 2024-06-13 | Chiesi Farmaceutici S.P.A. | Indoline derivatives as ddr1 and ddr2 inhibitors |
| ES3022533T3 (en) * | 2021-03-26 | 2025-05-28 | Chiesi Farm Spa | Indoline derivatives as ddrs inhibitors |
| CN113292493A (zh) * | 2021-06-23 | 2021-08-24 | 上海立科化学科技有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法 |
| WO2024216197A2 (en) * | 2023-04-13 | 2024-10-17 | Acelot, Inc. | Compounds and methods for treating protein aggregation diseases |
| US12453728B1 (en) | 2024-08-08 | 2025-10-28 | Redux Therapeutics, Llc | Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
| US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| WO1996040640A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
-
1997
- 1997-11-03 CA CA002272719A patent/CA2272719C/en not_active Expired - Fee Related
- 1997-11-03 IL IL12974497A patent/IL129744A0/xx unknown
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/en not_active Ceased
- 1997-11-03 CN CN97180033A patent/CN1238764A/zh active Pending
- 1997-11-03 EA EA199900416A patent/EA001539B1/ru not_active IP Right Cessation
- 1997-11-03 EP EP97945048A patent/EP0944602A1/en not_active Withdrawn
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/xx unknown
- 1997-11-03 NZ NZ335162A patent/NZ335162A/xx unknown
- 1997-11-03 BR BR9714364A patent/BR9714364A/pt not_active Application Discontinuation
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/ko not_active Expired - Fee Related
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 JP JP52446498A patent/JP3270764B2/ja not_active Expired - Fee Related
- 1997-11-03 SK SK654-99A patent/SK65499A3/sk unknown
- 1997-11-03 YU YU23499A patent/YU23499A/sh unknown
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/es unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/zh not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/es unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/es not_active Application Discontinuation
- 1997-11-25 ID IDP973763A patent/ID18995A/id unknown
- 1997-11-25 UY UY24789A patent/UY24789A1/es not_active Application Discontinuation
- 1997-11-25 GT GT199700122A patent/GT199700122A/es unknown
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/xx active
- 1997-11-26 MA MA24877A patent/MA26451A1/fr unknown
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/hr not_active Application Discontinuation
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/xx unknown
- 1997-11-26 AR ARP970105560A patent/AR010309A1/es unknown
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/fr unknown
-
1999
- 1999-04-30 IS IS5040A patent/IS5040A/is unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 BG BG108830A patent/BG108830A/bg unknown
- 1999-05-26 BG BG103434A patent/BG103434A/xx unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/no unknown
-
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/zh active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/cs not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9714364A (pt) | Amidas inibidoras da secreção de apo b/mtp | |
| BR9916567A (pt) | Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares | |
| BR9916565A (pt) | Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares | |
| IL141786A0 (en) | A pharmaceutical composition for treating diabetes containing an ap2 inhibitor | |
| BR9916484A (pt) | Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares | |
| BR9916486A (pt) | Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares | |
| MX9702175A (es) | Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol. | |
| BG107515A (en) | Therapeutic combination | |
| AU8995598A (en) | Product and method for the treatment of hyperlipidemia | |
| SI1509232T1 (sl) | Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni | |
| BR9916485A (pt) | Combinações de inibidores da proteìna de transferência do éster colesterìlico e derivados do ácido fìbrico em indicações cardiovasculares | |
| CA2347117A1 (en) | Methods for inhibiting diabetic complications | |
| DE69819482D1 (de) | Inhibitoren der cholesterolesterase | |
| AU2177701A (en) | Use of hmg-coa reductase inhibitors for treating seborrhea | |
| CO4650034A1 (es) | Amidas inhibidoras de la secrecion de apo b/mtp | |
| AU2002366442A1 (en) | Screening method for agents useful in treating diabetes | |
| ECSP972325A (es) | Amidas inhibidoras de la secrecion de apo b/mtp | |
| CA2184696A1 (en) | Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives | |
| IT1255470B (it) | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |